$EQ

Zedelmayer Christine sold $27K of EQ

Zedelmayer Christine (Sr. Vice President and COO) sold 9,821 shares of Equillium, Inc. (EQ) at $2.70 on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zedelmayer Christine
Published May 29, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

A disclosed open-market sale can marginally influence sentiment, but the 10b5-1 designation generally limits interpretability as a new negative fundamental signal.

02

Market read

Primarily a transparency/ownership-change datapoint; likely limited trading impact absent additional company-specific catalysts.

03

What to watch

The article provides only the sale details; it does not quantify total insider selling frequency, option exercises, or broader ownership changes that could contextualize the signal.

Relevance 6/10Novelty 2/10Timing: Filed after-hours on 2026-05-29; transaction dated 2026-05-27.

Background

The article is an SEC Form 4 insider transaction disclosure for Equillium, Inc. (EQ) by COO Christine Zedelmayer under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium COO sold 9,821 shares in an open-market transaction disclosed via Form 4, signaling insider liquidity activity.

Expected impact

Low near-term impact; any reaction is likely muted given the 10b5-1 plan context.

Evidence & confidence

The filing specifies a pre-arranged 10b5-1 plan, which reduces the informational content of the sale versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of weaker outlook; traders may still monitor for follow-on disclosures.

Key entities

  • Equillium, Inc.

    Subject of the insider transaction disclosure (Form 4).

  • Christine Zedelmayer

    Sr. Vice President and COO who sold shares.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP